title: Clinical experience with cabergoline, a new ergoline derivative, in the treatment of Parkinson's disease.
authors.affiliation: Farmitalia Carlo Erba Laboratories, Milan.
authors.forename: M C
authors.initials: MC
authors.lastname: Jori
authors.forename: M
authors.initials: M
authors.lastname: Franceschi
authors.forename: M C
authors.initials: MC
authors.lastname: Giusti
authors.forename: N
authors.initials: N
authors.lastname: Canal
authors.forename: R
authors.initials: R
authors.lastname: Piolti
authors.forename: L
authors.initials: L
authors.lastname: Frattola
authors.forename: S
authors.initials: S
authors.lastname: Bassi
authors.forename: E
authors.initials: E
authors.lastname: Calloni
authors.forename: A
authors.initials: A
authors.lastname: Mamoli
authors.forename: M
authors.initials: M
authors.lastname: Camerlingo
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000978:Antiparkinson Agents; D000077465:Cabergoline; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004873:Ergolines / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D009460:Neurologic Examination; D010300:Parkinson Disease / Q000188:drug therapy*
chemical_list: D000978:Antiparkinson Agents; D004873:Ergolines; D000077465:Cabergoline